Q
QuantAbundance

Notícias

Apenas manchetes de alto sinal - eventos macro, resultados, M&A, regulatório. Listicles e clickbait de analistas filtrados por padrão. Atualizado a cada hora.

31,211 signal articles · 70 in last 24h · 159,946 total before filter · latest 1h ago
70last 24h
823last 7d
125● bullish (7d)
81● bearish (7d)
214publishers
AllMacro167Earnings202M&A86Regulatory16Product15Analyst25
✕ clear all filtersSentiment:bullishneutralbearish✓ showing all (incl. clickbait)
GE Aerospace Q2 Earnings Call Highlights
MarketBeat77d agoneutral
GE Aerospace Q2 Earnings Call Highlights

GE Aerospace (NYSE:GE) reported double-digit growth across key second-quarter 2026 metrics and raised its full-year outlook, citing strong commercial services demand, improved operating execution and a backlog that management said provides visibility into the rest of the year. Chairman and CEO Larr

The Surprising Tech Rotation Boosting Stocks This Earnings Season
Barrons.com77d agoneutral
The Surprising Tech Rotation Boosting Stocks This Earnings Season

U.S. stocks remain deep in the throes of a major rotation heading into the teeth of the second-quarter earnings season, and the traditional August lull that follows, as investors take money from highflying tech sector and spread that cash across a host of old-economy bets. What’s happening alongside that “great rotation,” however, is also interesting, and likely keeping stocks afloat amid the broader tech declines.

UNH Stock Flashes Buy Signal On Massive Earnings Beat
Investor's Business Daily77d agobullish
UNH Stock Flashes Buy Signal On Massive Earnings Beat

UnitedHealth Group crushed Q2 earnings forecasts amid lower-than-expected benefit costs and gave a big boost to its full-year outlook. Humana, Centene and CVS Health all got a sizable lift from the warm reception for UnitedHealth's earnings report.

Investing.com77d agobullish
UnitedHealth shares surge on strong earnings beat and guidance

Investing.com -- UnitedHealth Group (NYSE:UNH) reported second quarter results that exceeded analyst expectations across earnings, revenue and guidance, sending shares up 7% premarket as investors responded positively to the healthcare giant's improved outlook.